Interleukin-1 Receptor Antagonist Modulates Inflammation and Scarring After Ligament Injury by Chamberlain, Connie S. et al.
Digital Commons @ George Fox University 
Faculty Publications - Biomedical, Mechanical, 
and Civil Engineering 
Department of Biomedical, Mechanical, and 
Civil Engineering 
2014 
Interleukin-1 Receptor Antagonist Modulates Inflammation and 
Scarring After Ligament Injury 
Connie S. Chamberlain 
University of Wisconsin - Madison 
Ellen M. Leiferman 
University of Wisconsin - Madison 
Kayt E. Frisch 
George Fox University, kfrisch@georgefox.edu 
Sarah E. Duenwald-Kuehl 
University of Wisconsin - Madison 
Stacey L. Brickson 
University of Wisconsin - Madison 
See next page for additional authors Follow this and additional works at: https://digitalcommons.georgefox.edu/mece_fac 
 Part of the Musculoskeletal System Commons, Rehabilitation and Therapy Commons, and the Sports 
Medicine Commons 
Recommended Citation 
Chamberlain, Connie S.; Leiferman, Ellen M.; Frisch, Kayt E.; Duenwald-Kuehl, Sarah E.; Brickson, Stacey L.; 
Murphy, William L.; Baer, Georffrey S.; and Vanderby, Ray, "Interleukin-1 Receptor Antagonist Modulates 
Inflammation and Scarring After Ligament Injury" (2014). Faculty Publications - Biomedical, Mechanical, 
and Civil Engineering. 82. 
https://digitalcommons.georgefox.edu/mece_fac/82 
This Article is brought to you for free and open access by the Department of Biomedical, Mechanical, and Civil 
Engineering at Digital Commons @ George Fox University. It has been accepted for inclusion in Faculty Publications 
- Biomedical, Mechanical, and Civil Engineering by an authorized administrator of Digital Commons @ George Fox 
University. For more information, please contact arolfe@georgefox.edu. 
Authors 
Connie S. Chamberlain, Ellen M. Leiferman, Kayt E. Frisch, Sarah E. Duenwald-Kuehl, Stacey L. Brickson, 
William L. Murphy, Georffrey S. Baer, and Ray Vanderby 
This article is available at Digital Commons @ George Fox University: https://digitalcommons.georgefox.edu/
mece_fac/82 
20
14
RESEARCH ARTICLE
Interleukin-1 receptor antagonist modulates inflammation and scarring
after ligament injury
Connie S. Chamberlain1, Ellen M. Leiferman1, Kayt E. Frisch2, Sarah E. Duenwald-Kuehl1, Stacey L. Brickson1,
William L. Murphy1,2, Geoffrey S. Baer1, and Ray Vanderby1,2
1Department of Orthopedics and Rehabilitation and 2Department of Biomedical Engineering, University of Wisconsin, Madison, WI, USA
Abstract
Ligaments have limited regenerative potential and as a consequence, repair is protracted and
results in a mechanically inferior tissue more scar-like than native ligament. We previously
reported that a single injection of interleukin-1 receptor antagonist (IL-1Ra) delivered at the
time of injury, decreased the number of M2 macrophage-associated inflammatory cytokines.
Based on these results, we hypothesized that IL-1Ra administered after injury and closer to peak
inflammation (as would occur clinically), would more effectively decrease inflammation and
thereby improve healing. Since IL-1Ra has a short half-life, we also investigated the effect of
multiple injections. The objective of this study was to elucidate healing of a medial collateral
ligament (MCL) with either a single IL-1Ra injection delivered one day after injury or with
multiple injections of IL-1Ra on days 1, 2, 3, and 4. One day after MCL injury, rats received either
single or multiple injections of IL-1Ra or PBS. Tissue was then collected at days 5 and 11. Both
single and multiple IL-1Ra injections reduced inflammatory cytokines, but did not change
mechanical behavior. A single injection of IL-1Ra also reduced the number of myofibroblasts
and increased type I procollagen. Multiple IL-1Ra doses provided no additive response and,
in fact, reduced the M2 macrophages. Based on these results, a single dose of IL-1Ra was better
at reducing the MCL-derived inflammatory cytokines compared to multiple injections.
The changes in type I procollagen and myofibroblasts further suggest a single injection of
IL-1Ra enhanced repair of the ligament but not sufficiently to improve functional behavior.
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Introduction
Ligament and tendon repair involves a complex cascade of
coordinated events involving various cell types, cytokines and
extracellular matrix (ECM) factors. The repair process ranges
from months to years and results in scar tissue mechanically
inferior to native tissue. Normal ligament healing after injury
undergoes inflammation, proliferation, and remodeling.
Neutrophils, macrophages, and T-lymphocytes initially infil-
trate the wound followed by fibroblasts, myofibroblasts,
endothelial cells and additional macrophages (1,2). These
cells form granulation tissue which expands to remodel
residual ECM, reorganizing intact portions of the ligament
and contributing to an inefficient healing response (1).
As healing continues, type I procollagen decreases, while
myofibroblasts and type III collagen increases (1).
Myofibroblasts serve in early wound contraction and scar
formation. The newly formed type III collagen serves as a
weak transient connection for the injured ligament and is an
indicator of scar formation. As remodeling progresses, the
scar matures and the ratio of type I to type III collagen
normalizes, improving the tensile strength of the compro-
mised region, but never fully returning to its original state
(3,4). In an improved healing scenario, granulation tissue
would develop within the confines of the injury, collagen type
I would regenerate rapidly, myofibroblasts numbers and type
III collagen production would be minimal, and native tissue
would regenerate to demonstrate pre-damage organization,
laxity and strength. Numerous approaches to stimulate a
regenerative scenario have been attempted, but none have
resulted in complete regeneration. Previous research from our
lab identified a number of cellular, vascular, and molecular
components integral to early healing (1,5,6). Specifically,
interleukin-1b (Il1b) and interleukin-1 receptor antagonist
(Il1ra) were found to be significantly up-regulated in the
healing medial collateral ligament (MCL) 3 days post-
transection compared to the intact ligament (7). Interleukin-
1 (Il1) gene expression levels decreased at day 7 but remained
significantly higher than the intact tissue (7). The M1
(classically activated) and M2 (alternatively activated) macro-
phages have also been reported to peak between days 3 and 5
(1). The M1 macrophages secrete pro-inflammatory medi-
ators, such as IL-1, and participate in the activation of various
cytotoxic processes, including the respiratory burst, which
creates extensive collateral damage and aberrant inflamma-
tion (8–10). In contrast to the M1 inflammatory macrophages,
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the M2 macrophages secrete potent anti-inflammatory cyto-
kines, such as interleukin-10 (IL-10), and may play important
roles in wound healing and restoration of tissue homeostasis
(11,12). Past research indicated that M1 macrophages can be
phenotypically converted into M2 anti-inflammatory macro-
phages. The M2 macrophages are then able to induce
myofibroblast apoptosis, serve as antigen presenting cells,
and decrease the magnitude and duration of inflammation
to promote wound healing (13,14). Controlling these early
inflammatory mediators and cell types may therefore modu-
late subsequent healing and diminish scar formation.
IL-1 is a pleiotropic inflammatory cytokine, exerting
distinct effects on various cell types involved in all phases of
healing. Receptors for IL-1 are found on inflammatory cells,
including neutrophils, macrophages, T and B lymphocytes,
which allow IL-1 to modulate immune-cell dominated
inflammation (10). IL-1 receptors are also localized to
fibroblasts, allowing for myofibroblast/matrix deposition-
controlled fibrogenesis (10). IL-1 produced within a wound
regulates production of multiple inflammatory mediators,
including chemokines that direct inflammatory cell infiltra-
tion and pain (15). In skin wound models, IL-1 receptor
knockout mice showed reduced inflammatory cell infiltration
and fibrosis, suggesting that IL-1 inhibition could provide
therapeutic value in attenuating scar formation (16).
IL-1Ra is an endogenous antagonist that binds to the IL-1
receptor with comparable affinity as IL-1, but requires a
10–100 molar excess to inhibit IL-1 activity (17,18). Mice with
Il1ra gene deletion were found to have an enhanced response to
IL-1, were more susceptible to infections, and were more likely
to develop spontaneously occurring inflammatory arthritis
(19–21). We previously reported that perioperative adminis-
tration of IL-1Ra reduced the MCL-derived inflammatory
cytokines and concomitantly increased the M2 macrophages
when administered to a rat ligament healing model, indicating
a potential therapeutic role for IL-1Ra (7). Indeed, the
recombinant form of IL-1Ra, Anakinra (Swedish Orphan
Biovitrum, Stockholm, Sweden), has been approved by FDA
for the treatment of rheumatoid arthritis and has a good safety
record (22–24). However, our previous results also indicated
no significant improvement in ligament mechanical behavior
after one injection of IL-1Ra during injury. Based on these
results, we first hypothesized that IL-1Ra administered after
injury and closer to peak inflammation would improve healing
in a therapeutic (i.e. more clinically relevant) manner. We then
hypothesized that multiple injections of IL-1Ra administered
after injury would provide an additive healing response
compared to one IL-1Ra injection. The objective of this
study was to therefore elucidate the effects of single IL-1Ra
injection delivered one day after injury or the effects of
multiple IL-1Ra injections delivered at post injury days 1, 2, 3,
and 4, on rat medial collateral ligament (MCL) healing.
Methods
IL-1Ra experimental model
Experimental procedures were approved by the University
of Wisconsin Institutional Animal Care and Use Committee. In
order to identify the influence of IL-Ra on MCL healing, 38
skeletally mature male Wistar rats (275–299 g) were randomly
divided into 4 groups and subjected to bilateral MCL
transections. The MCLs were transected, rather than torn, to
create uniform defects for healing. Skin was incised (1 cm) over
the medial aspect of the left and right stifles, exposing each
gracilis muscle and underlying MCL. The mid-point of each
MCL was completely transected. The transected edges were
then were positioned back to their natural state. The muscular,
subcutaneous and subdermal tissue layers were each repaired
with 4-0 Dexon suture. Animals were allowed unhindered cage
movement immediately after surgery. Animals were then
randomly divided into ‘‘single injection’’ or ‘‘multiple injec-
tions’’ groups. For the single injection experiment, rats were
treated with either a single 600 ng injection of rat recombinant
IL-1Ra (R&D Systems, Minneapolis, MN) or a single injection
of phosphate buffered saline (PBS; vehicle control for IL-1Ra),
SC over each MCL (n¼ 16 rats) at 18–24 hours post-injury.
For the multiple injection experiment, animals (n¼ 16)
received daily injections of 600 ng IL-1Ra (n¼ 8) or PBS
(vehicle control for IL-1Ra; n¼ 8) SC over each MCL, starting
at 18–24 hours post-injury and continuing on and until day 4
post-injury. For both experiments, MCLs were collected at 5
and 11 days post-injury and used for IHC/multiplex analysis
and mechanical testing, respectively. A day 5 collection was
chosen since our previous work showed macrophage infiltra-
tion and granulation tissue formation peaks at this time and we
were interested in the effects of IL-1Ra on macrophage
response and granulation tissue formation (1). A day 11
collection was chosen for mechanical testing since ligaments
are substantially compromised earlier making it more difficult
to obtain meaningful data. Ligaments used for IHC for both
single and multiple injection experiments were carefully
dissected and immediately embedded longitudinally in optimal
cutting temperature (O.C.T.) medium for liquid nitrogen flash
freezing. Tissue used for multiplex analysis was carefully
dissected and immediately snap-frozen. Animals used for
mechanical testing, were sacrificed and limbs were stored
in toto at 70 C until used.
Immunohistochemistry
In order to identify cellular and ECM changes within the
healing MCL after IL-1Ra treatment, IHC and histology
were performed on day 5 MCLs. Longitudinally positioned
cryospecimens were sectioned (5 mm thickness), mounted on
Colorfrost Plus (Fisher Scientific, Pittsburgh, PA) microscope
slides and maintained at 70 C. Cryosections were fixed in
acetone, exposed to 3% hydrogen peroxide to remove
endogenous peroxidase activity, blocked with Background
Buster (Innovex Biosciences, Richmond, CA) and incubated
with mouse primary antibodies. Mouse monoclonal anti-
bodies to CD68 (1:100, Abcam-Serotec, Raleigh, NC),
CD163 (1:100, Abcam-Serotec, Raleigh, NC), CD31 (1:100,
Abcam-Serotec, Raleigh, NC), a-smooth muscle actin (SMA;
no dilution, Abcam-Serotec, Raleigh, NC), and Ki-67 (1:100,
Dako, Carpinteria, CA) were utilized to identify the classic-
ally activated macrophages (M1), alternatively activated
macrophages (M2), endothelial cells, myofibroblasts and
proliferating cells, respectively. Mouse antibodies were also
used to identify type I procollagen (straight; SP1.D8;
Developmental Hybridoma, Iowa City, IA) and the scar
indicator, type III collagen (1:8000, Sigma-Aldrich, St. Louis,
MO). After primary antibody inbubation, sections were
incubated with biotin, and streptavidin-conjugated to horse-
radish peroxidase using the Stat Q IHC staining kit (Innovex
Biosciences, Richmond, CA). The bound antibody was then
visualized using diaminobenzidine (DAB). Stained sections
were dehydrated, cleared, cover-slipped and visualized using
light microscopy.
After staining, images of each IHC marker were collected
using a camera assisted microscope (Nikon Eclipse micro-
scope (Mellville, NY), model E6000 with an Olympus camera
(Center Valley, PA), model DP79). Within each IHC-stained
tissue section, five images were obtained; three images were
captured within the granulation tissue (granulation tissue
proximal edge, granulation tissue distal edge, center of
granulation tissue) and two images were captured away
from the granulation tissue (proximal end and distal end of the
MCL; Figure 1a). Images were obtained from 3 sections per
rat for a total of 15 images. Pictures captured for measurement
of endothelial cells, myofibroblasts, type I procollagen, and
type III collagen were quantified using Image J (National
Institutes of Health, NIH, Bethesda, MD). Briefly, images
were first converted to 8-bit files. The total area of each
ligament within each captured image was then measured. A
set threshold to identify DAB staining was applied (the
threshold was adjusted specifically for the IHC protein of
interest). Particle size was then adjusted (based on the protein
of interest). The resulting output was recorded, adjusted based
on the ligament area, and expressed as density/mm2. Images
of blood vessel lumen, proliferating cells, M1 and M2
macrophages were quantified manually. For all images, the
resulting output was recorded based on the area the image was
captured (ex: granulation tissue, proximal end, etc.) to later
determine any spatial influence of IL-1Ra within the MCL.
Histology
MCL sections were H&E stained to observe general morph-
ology of the healing ligaments. Tissue was observed for any
changes in cell distribution, collagen organization, and
granulation tissue size between treatment groups. To measure
granulation tissue size, images of the MCL were captured
using a camera assisted microscope (Nikon Eclipse micro-
scope, model E6000 with an Olympus camera, model DP79)
and the granulation tissue area was measured using Image J
(National Institutes of Health, NIH, Bethesda, MD; Figure
1a). Size of the granulation tissue was normalized to the total
MCL area and expressed as the percent normalized granula-
tion tissue.
Multiplex assay
To identify the influence of IL-1Ra on MCL cytokine
production, a rat 10-plex Luminex assay (Life Technologies,
Grand Island, NY) was performed using the day 5 MCLs.
MCLs were rinsed in Cell Wash Buffer (Bio-Rad, Hercules,
CA) and placed in Navy Bead Lysis Kit tubes containing a
Figure 1. Representative images of measure-
ment techniques. Low-magnification H&E
image of the day 5 MCL demonstrating the
regions where high magnification images
were captured (a). The circles indicate
regions on the MCL where representative
images were collected. The regions consist of
the granulation tissue (G.T.), G.T. distal edge,
G.T. proximal edge, distal end, and proximal
end of the ligament. The large black circle
encircles the granulation tissue. Image of the
mechanical testing device (bath) containing
the gripped MCL prior to mechanical testing
(b).
0.9–2.0 mm stainless steel bead blend, 3.2 mm stainless steel
balls (Next Advance, Averill Park, NY) and Lysing Solution
(Bio-Rad, Hercules, CA). Samples were homogenized for
10 minutes using a Bullet Blender (Next Advance, Averill
Park, NY). Supernatant was collected and used for
Bicinchoninic acid (BCA), to determine total protein con-
centration, and subsequent multiplex analysis. Multiplex
cytokine assays (Life Technologies, Grand Island, NY) were
performed according to the manufacturer’s instructions.
Diluted magnetic bead solution was vortexed, sonicated and
added to each well. Standards, MCLs samples, spleen
(serving as positive control), and lysis buffer (serving as
negative control) were added to the wells and incubated in
the dark, overnight at 4 C on a plate shaker. The following
day, samples were washed, incubated with biotinylated
detector antibody, and streptavidin-RPE solution. After
washing and re-suspension in working wash solution, samples
were quantified on a Luminex 200 instrument (Luminex,
Austin TX). Ten proteins were included in the assay,
including interleukin-1a (IL-1a), IL-1b, IL-10, interleukin-2
(IL-2), interleukin-12 (IL-12), interleukin-4 (IL-4), interleu-
kin-6 (IL-6), tumor necrosis factor- a (TNF-a), interferon-g
(IFN-g), and granulocyte macrophage-colony stimulating
factor (GM-CSF). Assessment of the multiplex assay was
performed by verifying each standard curve point was within
80–120% recovery, and 2 standard deviations above back-
ground. Cytokine concentrations were normalized to protein
concentration and expressed as ng of cytokine per mg of
tissue (ng/mg).
Mechanical testing
In order to assess the functional behavior of the healing
MCL after treatment with IL-1Ra, day 11 ligaments were
mechanically tested. Pull-to-failure analysis was performed as
previously described (25–27). After rat sacrifice the MCL was
removed with both femoral and tibial (FMT) insertion sites
intact, and the surrounding tissue was carefully excised
with special care taken to avoid damaging the insertion sites.
During preparation, the FMT complex remained hydrated
using PBS. The width and thickness of the MCL was
measured optically and the cross-sectional area for the
ligament was estimated assuming an elliptical cross section.
The hydrated femur-MCL-tibia complex was mounted in
a custom made testing bath and mechanical testing
machine (Figure 1b). Optical markers (silicon gel with
graphite) were applied to the ligament on the insertion
sites and the displacement was recorded optically. After pre-
loading to 0.1 newtons (N), dimension measurements
were recorded and the ligament was preconditioned (cyclic-
ally loaded to 1% strain for 10 cycles). The MCL was
then pulled to failure at a rate of 10% strain per second.
Failure force was documented as the highest load prior to
failure of the ligament. The slope of the linear portion of the
line relating stress to elongation was used to calculate
stiffness.
Statistical analysis
For the IHC results, MCL regions were subgrouped (granu-
lation tissue, outside of granulation tissue, and total MCL) to
identify any potential spatial differences of each factor
measured. Student’s t-tests were then used to examine
treatment differences for both IHC and mechanical results.
For the multiplex data, analysis of variance (ANOVA) was
used to examine treatment differences. If the overall p value
for the F-test in ANOVA was significant, Fisher’s least
significant difference (LSD) post-hoc comparisons were
performed. Experimental results are presented as the
means ± standard error of the mean (S.E.M). If p50.050,
data were considered statistically significant. Computations
were performed using KaleidaGraph, version 4.03 (Synergy
Software, Inc., Reading, PA).
Results
H&E staining
To first determine if IL-1Ra modulated general ligament
morphology, H&E staining of the tissue was performed.
No changes in cell distribution, cell number, or collagen
organization were observed between treatment groups.
Granulation tissue size normalized to the total MCL area
also did not differ (p40.050) between treatments, regardless
of the number of IL-1Ra injections (Figure 2a and b).
Immunohistochemistry
Components of inflammation and granulation tissue forma-
tion, including the M1 and M2 macrophages, proliferating
cells, endothelial cells, blood vessel lumen, and myofibro-
blasts, were examined since we previously reported significant
regulation by IL-1Ra when administered perioperatively. No
significant changes were observed in M1 macrophage numbers
after single (p¼ 0.325) or multiple (p¼ 0.617) injections of
IL-1Ra (Table 1). In contrast, multiple injections with IL-1Ra
significantly reduced (p50.001; 5.50 ± 1.50 cells/mm2;
Figure 3a–i) the granulation tissue-localized M2 macrophages
compared to PBS (22.00 ± 0.19 cells/mm2). No significant
changes (p¼ 0.568) were observed in M2 macrophage num-
bers after a single injection of IL-1Ra (PBS, 35.53 ± 4.04 cells/
mm2 versus IL-1Ra, 31.61 ± 4.83 cells/mm2). Myofibroblasts
were decreased (p¼ 0.025) with a single injection of IL-1Ra
(2.19 ± 0.80 104 density/mm2) throughout the entire liga-
ment compared to PBS (6.00 ± 0.75 104 density/mm2;
Figure 3j–r) whereas no treatment differences (p¼ 0.211)
were noted after multiple IL-1Ra treatments (PBS, 0.35 ±
0.22 104 density/mm2 versus IL-1Ra, 1.54 ± 0.77
104 density/mm2). Regardless of injection number, prolifer-
ating cells, endothelial cells, and blood vessel lumen were not
significantly (p40.050) different after IL-1Ra treatment
(Table 1).
To further assess whether IL-1Ra improved healing and
reduced scar, type I procollagen and type III collagen were
measured. Type I procollagen significantly (p¼ 0.029)
increased after a single injection of IL-1Ra (PBS,
1.48 ± 0.38 103 density/mm2 versus IL-1Ra, 8.15 ±
1.62 103 density/mm2; Figure 4a–j). Procollagen also
tended to increase (p¼ 0.069) after daily IL-1Ra injections
(PBS, 0.19 ± 0.09 103 density/mm2 versus IL-1Ra, 3.42 ±
1.02 103 density/mm2). No changes were noted between
treatments in the scar-indicator, type III collagen (Table 1).
Multiplex results
The IHC results identified specific cells and ECM factors
influenced by IL-1Ra treatment during MCL healing. This
set of experiments examined the influence of IL-1Ra on
MCL-derived cytokine production. As Figure 5(a) and (b)
indicate, both IL-1 a (single PBS, 0.82 ± 0.10 ng/mg ver-
sus single IL-1Ra, 0.49 ± 0.00 ng/mg; and multiple PBS,
0.82 ± 0.10 ng/mg versus multiple IL-1Ra, 0.41 ± 0.05 ng/mg)
and IL-1 b (single PBS, 5.26 ± 0.06 ng/mg versus single IL-
1Ra, 4.43 ± 0.07 ng/mg; and multiple PBS, 5.40 ± 0.03 ng/mg
versus multiple IL-1Ra, 4.85 ± 0.07 ng/mg) were significantly
down-regulated after single and multiple injections of IL-1Ra.
Similarly, IL-6 (Figure 5c) was also reduced after single
(PBS, 0.65 ± 0.02 ng/mg versus IL-1Ra, 0.36 ± 0.02 ng/mg)
and multiple (PBS, 0.48 ± 0.01 ng/mg versus IL-1Ra,
0.37 ± 0.02 ng/mg) injections of IL-1Ra. In contrast, IL-12
(Figure 5d) was up-regulated by multiple (PBS,
Figure 2. Size of granulation tissue of the
MCL after PBS or IL-1Ra treatment. Graph
demonstrating the effect of single or multiple
treatments of PBS or IL-1Ra on granulation
tissue size (a). No significant differences
were noted. Data was considered significant
when p50.05. Values are expressed as mean
cell numbers ± S.E.M. Representative micro-
graphs of H&E stained day 5 MCLs after
single or multiple treatments of PBS or IL-
1Ra (b). Black lines encircling the granula-
tion tissue represent examples of how the
granulation tissue was measured.
Table 1. Immunohistochemistry results of MCL cellular and ECM factors after treatment with IL-1Ra.
IHC Factor p Value Single PBS Single IL-1Ra p Value Multiple PBS Multiple IL-1Ra
M1 Macrophages (Ave. cells/mm2 ) 0.325 86.34 ± 13.35 71.18 ± 2.22 0.617 57.55 ± 4.28 53.06 ± 7.09
Proliferating cells (Ave. cells/mm2 ) 0.676 31.92 ± 3.38 28.71 ± 6.27 0.368 45.58 ± 11.22 60.48 ± 9.48
Endothelial cells (Ave. density/mm2 ) 0.250 2.54 ± 0.10 103 3.38 ± 0.62 103 0.139 4.09 ± 0.54 103 5.2 ± 0.26 103
Blood vessel lumen (Ave. lumen number/mm2) 0.294 2.38 ± 0.56 4.06 ± 1.27 0.215 6.82 ± 0.94 4.60 ± 1.18
Type III collagen (Ave. density/mm2 ) 0.363 6.53 ± 0.16 102 6.28 ± 0.19 102 0.794 5.31 ± 0.25 102 5.39 ± 0.12 102
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0.40 ± 0.02 ng/mg versus IL-1Ra, 0.56 ± 0.02 ng/mg) doses
of IL-1Ra but decreased by a single dose (PBS,
0.53 ± 0.02 ng/mg versus IL-1Ra, 0.45 ± 0.01 ng/mg). The
anti-inflammatory cytokine, IL-10, was not significantly
regulated by IL-1Ra treatment (p¼ 0.195). Levels of GM-
CSF, TNF-a, IFN-g, IL-2, and IL-4 were below the detectable
sensitivity range.
Mechanical testing
Ligament failure force and stiffness were measured using day
11 healing MCLs. A single injection of IL-1Ra, 1 day after
injury, tended to increase force (p¼ 0.108; Figure 6a), but had
no significant effect on stiffness (p¼ 0.280; Figure 6b) when
compared to the control specimens. Multiple injections of
IL-1Ra provided no additional mechanical influence on
failure force (p¼ 0.485; Figure 6a) or stiffness (p¼ 0.564;
Figure 6b) when compared to the PBS controls data.
Mechanical results show that IL-1Ra treatment did neither
significantly alter the behavior of the healing ligaments nor
inhibit their functional recovery at day 11.
Discussion
The goal of this study was to further elucidate the temporal
and spatial dependence of exogenous IL-1Ra on ligament
healing. We previously reported improved ligament healing
after perioperative (30 minutes prior and 3 hours post-injury)
intraperitoneal (IP) injection of IL-1Ra (7). However, because
ligament ruptures are not typically treated immediately during
injury, the current study was performed to evaluate the
influence of IL-1Ra administered in a more therapeutic
manner, one day after injury. Results demonstrated that a
single IL-1Ra injection administered subcutaneously over the
MCL reduced the number of myofibroblasts and the pro-
inflammatory cytokines (IL-1a, IL-1b, IL-12 and IL-6),
increased type I procollagen, and tended to increase tensile
strength. Multiple IL-1Ra injections initiated one day after
injury likewise decreased IL-1a, IL-1b, and IL-6 but
increased IL-12, decreased the number of M2 macrophages,
and had no significant influence on myofibroblasts or tensile
strength. These results further support the concept that
exogenous IL-1Ra can modulate the granulation tissue and
scar forming components of the healing MCL and have no
detrimental effect on mechanical function.
IL-1 induces production of a number of inflammatory
mediators, including nitric oxide, prostaglandins, TNF-a and
IL-6. The pro-inflammatory and leukocyte chemotactic
functions of IL-1 suggest it contributes to the pathogenesis
of acute injury. Therefore, interruption of IL-1 activity via
IL-1Ra could significantly alter tissue response after injury.
The decrease in IL-1a and IL-1b suggests IL-1Ra directly
inhibited the IL-1 mediated pathway and/or suppressed
infiltration of inflammatory cells that secrete IL-1. Previous
studies have shown that IL-1 blockade inhibited IL-6
production (28–30) and cell infiltration (28) in the murine
wound. Based on the decrease in IL-6, the current results
suggest that IL-1Ra directly modulated the IL-1 pathway
rather than inflammatory cell infiltration since macrophages
were not significantly (in the case of the M1 macrophages) or
consistently (in the case of the M2 macrophages) regulated byF
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IL-1Ra. These results are in contrast to our prior report
indicating that IL-1Ra treatment increased day 5 IL-1a, and
did not alter IL-6 or IL-1b levels; by 11 days post-injury both
IL-1a and IL-1b had decreased. The SC injection of IL-1Ra
over the MCL in the current study may have elicited a quicker
response by targeting MCL-derived IL-1 and IL-6 compared
to IP IL-1Ra administration.
Circulating monocytes differentiate into macrophages
that are broadly subgrouped as classically activated M1 or
alternatively activated M2 macrophages. The M2 macrophage
phenotype, characterized by a cytokine profile of IL-12low,
IL-10high, IL-1Rahigh, IL-1blow and increased angiogenic
mediators, are involved in tissue remodeling, reducing acute
inflammation and regulating tissue homeostasis (31–33).
Thus an upregulation of the M2 phenotype within the wound
may accelerate healing. Our previous work demonstrated
a significant increase in the M2 macrophages, angiogenesis,
IL-10 and a decrease in IL-12 after IL-1Ra treatment
perioperatively (7). In the current study, IL-1Ra did not
increase the M2 macrophages or angiogenic factors. The
addition of multiple IL-1Ra doses also did not upregulate the
M2 phenotype, but rather, decreased the M2 macrophages
and increased IL-12. After injury, monocytes migrate
from the circulation, extravasate through the endothelium
and differentiate into macrophages with an M1 or M2
phenotype, based on their environmental cues. IL-1Ra
administered SC directly over the MCL would likely target
the monoctyes/macrophages localized to the MCL, especially
if IL-1Ra injection was administered one day post injury. In
contrast, an IP injection of IL-1Ra would provide a more
systemic delivery mechanism which could potentially influ-
ence a greater number of monocytes traveling to the wound.
Compared to our previous study in which IL-1Ra was
delivered IP the day of injury, the single SC dose of IL-1Ra
localized to the MCL had less influence on the circulating
monocytes/macrophages to induce M2 polarization and
subsequent M2-induced angiogenesis and cytokine
production.
The decrease in M2 macrophages and increase in IL-12
after multiple IL-1Ra injections may have resulted from the
delivery method chosen for this study. A study by Jensen
compared the ligament inflammatory cell infiltrate of com-
monly used prolotherapies versus needlestick only (34).
The needlestick alone resulted in increased inflammatory
cell infiltrate, similar to the prolotherapies. The multiple
needle sticks in the current study could then have
influenced the inflammatory response, which may explain
the decrease in the anti-inflammatory M2 macrophages and
the increase IL-12.
The increase in type I procollagen, decrease in myofibro-
blasts and tendency to increase tensile strength after a single
IL-1Ra injection, suggests that IL-1Ra is capable of reducing
scar formation within the healing ligament. Despite these
improvements, IL-1Ra did not recover the mechanical
properties of the tissue to its native state. The lack of true
significance in tensile load suggests that although type I
Figure 5. Multiplex results of cytokines regulated by IL-1Ra. Graphs show the effects of PBS and IL-1Ra on MCL-derived IL-1a (a), IL-1b (b), IL-6
(c), and IL-12 (d) production. Blockade of the IL-1 activation resulted in a decrease of IL-1a (a), IL-1b (b), and IL-6 (c) after single and multiple
IL-1Ra injections. A single injection of IL-1Ra significantly decreased IL-12 whereas multiple IL-1Ra injections increased IL-12(d). Beneath graph,
p value indicates ANOVA results. a,b,c indicates within a graph, bars without a common superscript letter differ (results of Fisher’s LSD post-hoc
pairwise analysis, p50.05). Values are expressed as normalized cytokine concentration (ng cytokine/mg tissue weight) ± S.E.M.
procollagen production was increased by IL-1Ra, the forma-
tion of type I collagen fibers had not yet occurred. Perhaps
a mechanical improvement would manifest later in healing,
since biologically, IL-1Ra elicited a more favorable response.
Taken together, these results suggest that a concomitant
improvement in scar formation and tensile strength may be
possible by optimizing the timing and localization of IL-1Ra
in order to modulate the necessary inflammatory and ECM
factors necessary for healing.
To compensate for the short half-life of IL-1Ra (4–6 hours),
multiple IL-1Ra injections were also included as a treatment
group and were found to provide no additional improve-
ments in healing. Multiple IL-1Ra injections may have
even reduced the ability to control scar formation based on
the lack of change in myofibroblasts and tensile strength
and only a trend increase in type I procollagen. The lack
of improvement between single and multiple injections may
suggest that a small window of opportunity is available for
IL-1Ra to influence both inflammation and early scar forma-
tion. These results also suggest that other biological factors
likely play a pertinent role in controlling scar formation.
Conclusions
Overall, IL-1Ra administration SC after injury reduced
selected pro-inflammatory components and scar-modulating
factors, but despite an increase in type I procollagen, IL-1Ra
did not significantly improve ligament mechanics. The
modulation of inflammation and ECM factors appears to be
dependent on the time of intervention and may involve cross-
talk between immune and connective tissue cells. Clinically,
IL-1Ra may be appropriate as an anti-inflammatory agent
during surgical repair of the tendon or ligament or as a
downstream modulator to scar formation although detailed
behaviors and mechanisms remain to be elucidated.
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